Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210192

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210192

Remdesivir Global Market Report 2023

Published: Pre-Order
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Remdesivir Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on remdesivir market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for remdesivir ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The remdesivir market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Route Of Administration: Oral; Intravenous

2) By Dosage Form: Tablets; Frozen Solution; Lypholized Solution

3) By Distribution Channel: Hospitals; Clinics; Drug Stores/Pharmacies; Online; Other Distribution Channels

Companies Mentioned: Gilead Sciences Inc.; Bright Gene; Hainan Haiyao; Kelun Pharma; Hunan Warrant Pharmaceutical

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the remdesivir market are: Gilead Sciences Inc., Bright Gene, Hainan Haiyao, Kelun Pharma, Hunan Warrant Pharmaceutical, Cipla, Pfizer, Merck, Cayman Chemical, and Dr. Reddy's Laboratories.

The global remdesivir market is expected to grow from $2.87 billion in 2021 to $3.77 billion in 2022 at a compound annual growth rate (CAGR) of 31.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The remdesivir market is expected to reach $11.17 billion in 2026 at a CAGR of 31.2%.

The remdesivir market consists of sales of nucleotide analog and Veklury. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Remdesivir refers to a class of drugs called antivirals that are used to treat hospitalised adults and children 28 days of age and older who weigh at least 6.6 pounds for coronavirus disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus (3 kg). who have a significant risk of developing severe COVID-19, which could result in hospitalisation and death

North America is the largest region in the remdesivir market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the remdesivir market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main routes of administration in remdesivir are oral and intravenous. Intravenous generally relates to a method of administering a drug or other substance into a vein using a syringe or tube. The different dosage forms include tablets, frozen solutions, and lyophilized solutions and are distributed through various channels such as hospitals, clinics, drug stores/pharmacies, online, and others.

The increasing prevalence of COVID-19 disease globally is a key factor driving the growth of the remdesivir market. According to the World Health Organization (WHO), there were 10,719,946 cases of COVID-19 including 5,17,337 deaths reported to WHO on 24th May 2020, and this number is expected to grow shortly. American authorities have approved the immediate use of experimental redeliver, which seemed to help several patients with coronavirus recover more quickly, and this was the first drug that helped to overcome COVID-19, which killed more than 300,000 individuals around the globe. Gilead Sciences, which is working to develop the drug, has seen its share of New York trading increase by more than 5.5% in the first quarter of 2020. The United States and Asia shares have increased expectations that an experimental drug will further support in the control of COVID-19 symptoms. Therefore, the increasing prevalence of COVID-19 disease across different parts of the globe is expected to drive the growth of the remdesivir market.

The high cost associated with the drug is a key factor hampering the growth of the market. Gilead Sciences which produces remdesivir donates its initial supply of 1.5 million doses, but the company has demonstrated that it would have to begin charging the drug for sustainable production. There are various speculations on the pricing of the drug. According to the Institute for Clinical and Economic Review (ICER), the estimated price of Remdesivir would be between $4,580 to $5,080. The higher-end pricing of remdesivir is expected to hinder the growth of the market.

Also, Gilead licensed redeliver for COVID-19 to companies manufacturing generic drugs for sale in 127 countries. Five generic companies Cipla, Ferozsons Labs, Hetero Labs, Jubilant Lifesciences, and Mylan will have the right to manufacture and sell generic versions of the drug in mostly lower-income countries, as well as higher-income countries that face significant obstacles to healthcare access. The licensees won't pay royalties to Gilead until the pandemic is called off or until a second drug is approved. This is likely to challenge the growth of the market.

In March 2020, Gilead Sciences, Inc., an America-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, acquired Forty Seven Inc. for $4.9 billion. This acquisition will strengthen Gilead's immuno-oncology research and development portfolio. Forty Seven Inc. is a US-based clinical-stage immuno-oncology company focused on developing novel checkpoint therapies.

The countries covered in the remdesivir market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The remdesivir market research report is one of a series of new reports from The Business Research Company that provides remdesivir market statistics, including remdesivir industry global market size, regional shares, competitors with a remdesivir market share, detailed remdesivir market segments, market trends and opportunities, and any further data you may need to thrive in the remdesivir industry. This remdesivir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r2045

Table of Contents

1. Executive Summary

2. Remdesivir Market Characteristics

3. Remdesivir Market Trends And Strategies

4. Remdesivir Markett - Macro Economic Scenario

4.1 COVID-19 Impact On Remdesivir Market

4.2 Ukraine-Russia War Impact On Remdesivir Market

4.3 Impact Of High Inflation On Remdesivir Market

5. Remdesivir Market Size And Growth

  • 5.1. Global Remdesivir Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Remdesivir Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Remdesivir Market Segmentation

  • 6.1. Global Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Oral
  • Intravenous
  • 6.2. Global Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Tablets
  • Frozen Solution
  • Lypholized Solution
  • 6.3. Global Remdesivir Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospitals
  • Clinics
  • Drug Stores/Pharmacies
  • Online
  • Other Distribution Channel

7. Remdesivir Market Regional And Country Analysis

  • 7.1. Global Remdesivir Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Remdesivir Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Remdesivir Market

  • 8.1. Asia-Pacific Remdesivir Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Remdesivir Market

  • 9.1. China Remdesivir Market Overview
  • 9.2. China Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Remdesivir Market

  • 10.1. India Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Remdesivir Market

  • 11.1. Japan Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Remdesivir Market

  • 12.1. Australia Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Remdesivir Market

  • 13.1. Indonesia Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Remdesivir Market

  • 14.1. South Korea Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Remdesivir Market

  • 15.1. Western Europe Remdesivir Market Overview
  • 15.2. Western Europe Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Remdesivir Market

  • 16.1. UK Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Remdesivir Market

  • 17.1. Germany Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Remdesivir Market

  • 18.1. France Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Remdesivir Market

  • 19.1. Eastern Europe Remdesivir Market Overview
  • 19.2. Eastern Europe Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Remdesivir Market

  • 20.1. Russia Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Remdesivir Market

  • 21.1. North America Remdesivir Market Overview
  • 21.2. North America Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Remdesivir Market

  • 22.1. USA Remdesivir Market Overview
  • 22.2. USA Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Remdesivir Market

  • 23.1. South America Remdesivir Market Overview
  • 23.2. South America Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Remdesivir Market

  • 24.1. Brazil Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Remdesivir Market

  • 25.1. Middle East Remdesivir Market Overview
  • 25.2. Middle East Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Remdesivir Market

  • 26.1. Africa Remdesivir Market Overview
  • 26.2. Africa Remdesivir Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Remdesivir Market, Segmentation By Dosage Form, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Remdesivir Market Competitive Landscape And Company Profiles

  • 27.1. Remdesivir Market Competitive Landscape
  • 27.2. Remdesivir Market Company Profiles
    • 27.2.1. Gilead Sciences, Inc.
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Bright Gene
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Hainan Haiyao
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Kelun Pharma
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Hunan Warrant Pharmaceutical
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Remdesivir Pipeline Analysis

29. Key Mergers And Acquisitions In The Remdesivir Market

30. Remdesivir Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Historic And Forecast Inflation Rates
  • 31.4. Research Inquiries
  • 31.5. The Business Research Company
  • 31.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!